BLTE Overview

ABIVAX Société Anonyme: The biotechnology company reached the $100 mark on October 30, 2025, driven by its lead drug candidate, Obefazimod, which is in a pivotal phase III trial for ulcerative colitis. The stock rose from $7.83 in July 2025 to an all-time high of $138.49 in December 2025.

Nutex Health Inc.: This healthcare services company crossed the $100 threshold on April 9, 2025, reflecting significant revenue growth and profitability, with total revenue of $723.6 million for the first nine months of 2025. The stock increased from $33.56 in November 2024 to a peak of $193 in December 2025.

Cidara Therapeutics Inc.: Cidara reached the $100 milestone on October 1, 2025, following its agreement to be acquired by Merck for $221.50 per share. The stock price rose from $18.98 in November 2024, highlighting its growth potential in preventive influenza therapy.

Palvella Therapeutics Inc.: The company, focused on rare diseases, hit the $100 mark on November 24, 2025, after announcing positive results from its phase 2 study. The stock climbed from $25 in March 2025 to a peak of $112 in December 2025, reflecting investor confidence in its ongoing trials.

Revised Price Target: The average one-year price target for Belite Bio, Inc. has been increased to $188.02 per share, reflecting a 62.05% rise from the previous estimate of $116.02.

Analyst Range: Current analyst targets for Belite Bio range from a low of $141.40 to a high of $210.00 per share, indicating a 24.29% increase from the last reported closing price of $151.27.

Fund Sentiment: There has been a significant increase in institutional interest, with 45 funds reporting positions in Belite Bio, a 50% rise in the last quarter, and total shares owned by institutions increasing by 2,316.22% to 2,304K shares.

Major Shareholders: Key institutional shareholders include Ra Capital Management with 875K shares, Rtw Investments and Vestal Point Capital each with 312K shares, and Soleus Capital Management with 210K shares.